Compass Therapeutics
CMPX
77 hedge funds and large institutions have $135M invested in Compass Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 13 closing their positions.
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
1% more funds holding
Funds holding: 76 → 77 (+1)
2.67% less ownership
Funds ownership: 70.39% → 67.72% (-2.7%)
20% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 25
24% less capital invested
Capital invested by funds: $177M → $135M (-$42M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.06M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$4.9M |
| 3 |
Morgan Stanley
New York
|
+$679K |
| 4 |
ECM
Element Capital Management
New York
|
+$509K |
| 5 |
BlackRock
New York
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$9.75M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$2.46M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.84M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.26M |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$322K |
CMPX Hedge Fund Activity: Q4 2023 in Review
77 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q4 2023, worth a combined $135M — down 24% from $177M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CMPX positions and 13 closed out — a net gain of 2 holders — while 20 added to existing stakes and 25 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6.06M. The largest seller was Braidwell, cutting an estimated $9.75M.
- 77 institutional investors held Compass Therapeutics (CMPX) as of Q4 2023, up from 76 in Q3 2023.
- Funds reported $135M of Compass Therapeutics stock for Q4 2023, down 24% quarter-over-quarter.
- 15 funds opened new Compass Therapeutics positions in Q4 2023 and 13 closed out, a net change of +2 holders.
- The largest Compass Therapeutics buyer in Q4 2023 was Adage Capital Partners, an estimated $6.06M added.
- The largest Compass Therapeutics seller in Q4 2023 was Braidwell, an estimated $9.75M sold.
Based on aggregated 13F filings for Q4 2023.